SHENZHEN, November 19, 2026 - (ACN Newswire) -The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.
Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.
Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints [2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.
Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs.
Read More: https://www.acnnewswire.com/press-release/english/111707/